ALNY vs. GMAB: Alnylam Pharmaceuticals vs. Genmab Stock Comparison
How do Alnylam Pharmaceuticals (ALNY) and Genmab (GMAB) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Alnylam Pharmaceuticals (ALNY) and Genmab (GMAB) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
Alnylam Pharmaceuticals (ALNY) trades as ordinary local shares, while Genmab (GMAB) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ALNY | GMAB |
|---|---|---|
| Name | Alnylam Pharmaceuticals, Inc. | Genmab A/S American Depositary Shares |
| Country/Region | United States | Denmark |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 20.89 billion USD | 32.98 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 1, 2004 | June 1, 2009 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Total Return (1Y) | -64.57% | 91.17% |
| Total Return (3Y, Annualized) | -1.58% | 20.70% |
| Total Return (5Y, Annualized) | -3.13% | 3.98% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Volatility (1Y, Annualized) | 54.08% | 45.68% |
| Beta (5Y) | 0.45 | 0.72 |
| Max Drawdown (5Y) | -68.25% | -61.79% |
| Avg. Volume (3M) | 1.90M | 4.09M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Sharpe Ratio (1Y) | -1.27 | 1.90 |
| Sortino Ratio (1Y) | -1.45 | 3.82 |
Profitability
ROE (TTM)
Both companies show strong equity returns, but Alnylam Pharmaceuticals (ALNY) at 138.07% is the standout with ROE above its industry range; Genmab (GMAB) at 12.07% also sits in the top quartile.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
138.07%
- ALNY
- 138.07%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.07%
- Max
- 109.18%
- GMAB
- 12.07%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Alnylam Pharmaceuticals (ALNY) at 52.85% keeps the most of each sales dollar — above its industry’s net margin range — and Genmab (GMAB) at 16.97% also retains a top-quartile share.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.85%
- ALNY
- 52.85%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
16.97%
- Max
- 18.05%
- GMAB
- 16.97%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Alnylam Pharmaceuticals (ALNY) at 23.72% and Genmab (GMAB) at 37.15% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.72%
- Max
- 83.12%
- ALNY
- 23.72%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.15%
- Max
- 83.12%
- GMAB
- 37.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| ROE (TTM) | 138.07% | 12.07% |
| ROA (TTM) | 9.51% | 8.24% |
| Net Margin (TTM) | 52.85% | 16.97% |
| Operating Margin (TTM) | 23.72% | 37.15% |
| Gross Margin (TTM) | 77.28% | 92.67% |
Growth
Revenue Growth
Alnylam Pharmaceuticals (ALNY) at 65.19% sits in the top revenue growth quartile, while Genmab (GMAB) at 19.19% is closer to the peer norm — faster top-line expansion for ALNY.
EPS Growth
Only one side can be read here: Genmab (GMAB) reports EPS growth of -9.23%, ranked against its industry; Alnylam Pharmaceuticals (ALNY) has no EPS growth figure this period.
Growth Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Revenue Growth (YoY) | 65.19% | 19.19% |
| Revenue Growth (3Y CAGR) | 52.98% | 21.23% |
| EPS Growth (YoY) | -- | -9.23% |
| EPS Growth (3Y CAGR) | -- | 8.48% |
Financial Strength
Current Ratio (MRQ)
Alnylam Pharmaceuticals (ALNY) at 2.48 keeps current ratio within its industry’s typical mid-range, while Genmab (GMAB) at 2.45 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for GMAB.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.48
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ALNY
- 2.48
- Q1
- 2.47
- Min
- 0.10
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.45
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- GMAB
- 2.45
- Min
- 0.10
Debt / Equity (MRQ)
Both Alnylam Pharmaceuticals (ALNY) at 0.83 and Genmab (GMAB) at 0.82 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.83
- Max
- 1.42
- ALNY
- 0.83
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.82
- Max
- 1.42
- GMAB
- 0.82
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Current Ratio (MRQ) | 2.48 | 2.45 |
| Debt / Equity (MRQ) | 0.83 | 0.82 |
| Net Debt / EBITDA | -0.57 | 2.45 |
Dividends
Dividend Yield (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither Alnylam Pharmaceuticals (ALNY) nor Genmab (GMAB) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ALNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- GMAB
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Alnylam Pharmaceuticals (ALNY) at 7.88 sits in the cheaper P/E ratio quartile, while Genmab (GMAB) at 45.84 sits in the richer quartile — a clear split in what investors pay for each dollar of trailing earnings.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.88
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- ALNY
- 7.88
- Min
- 0.07
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
45.84
- Max
- 85.34
- GMAB
- 45.84
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
On P/S ratio, both Alnylam Pharmaceuticals (ALNY) at 4.17 and Genmab (GMAB) at 7.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.17
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ALNY
- 4.17
- Q1
- 3.01
- Min
- 0.01
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.68
- Max
- 58.18
- Q3
- 25.77
- GMAB
- 7.68
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Alnylam Pharmaceuticals (ALNY) at 5.79 and Genmab (GMAB) at 5.36 are valued close to their industries’ norm against book — neither stands out from peers.
ALNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.79
- Max
- 13.53
- Q3
- 6.54
- ALNY
- 5.79
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
GMAB
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.36
- Max
- 13.53
- Q3
- 6.54
- GMAB
- 5.36
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ALNY | GMAB |
|---|---|---|
| P/E Ratio (TTM) | 7.88 | 45.84 |
| P/S Ratio (TTM) | 4.17 | 7.68 |
| P/B Ratio (MRQ) | 5.79 | 5.36 |
| Free Cash Flow Yield (TTM) | 1.57% | 2.59% |